



Open PHACTS Practical Semantics For Drug Discovery

Lee Harland (CTO)


Bio-IT World 2014







"Let me compare MW, logP and PSA for launched inhibitors of human & mouse oxidoreductases"








Pre-competitive Informatics:

Pharma are all accessing, processing, storing & re-processing external research data





A single, shared solution.

X

Repeat @ each company

Funded under IMI March 2011-14

Lowering industry firewalls: pre-competitive informatics in drug discovery Nature Reviews Drug Discovery (2009) 8, 701-708 doi:10.1038/nrd2944





Open PHACTS Mission: Integrate Multiple Research Biomedical Data Resources Into A Single Open & Free Access Point





The Open PHACTS Discovery Platform

- Cloud-Based "Production" Level System. Secure & Private
- Guided By Business
 Questions
- Uses Semantic Web
 Technology <u>But</u> provides
 a simple REST-ful API for
 the everyone else



Drug Discovery Today

Volume 18, Issues 17-18, September 2013, Pages 843-852



Review

Scientific competency questions as the basis for semantically enriched open pharmacological space development

Kamal Azzaoui¹, Edgar Jacoby¹⁴, Stefan Senger², Emiliano Cuadrado Rodríguez³, Mabel Loza³, Barbara Zdrazil⁴, Marta Pinto⁴, Antony J. Williams⁵, Victor de la Torre⁶, Jordi Mestres⁷, Manuel Pastor⁷, Olivier Taboureau⁸, Matthias Rarey⁹, Christine Chichester¹⁰, Steve Pettifer¹¹, Niklas Blomberg^{12,8}, Lee Harland¹³. Bryn Williams-Jones¹³, Gerhard F. Ecker⁴. ♣ . ►

http://dx.doi.org/10.1016/j.drudis.2013.05.008



Web Semantics: Science, Services and Agents on the World Wide Web






In Press, Accepted Manuscript - Note to users

API-centric Linked data integration: The open PHACTS discovery platform case study

Paul Groth^{a, ▲ ™, ™, Antonis Loizou^a, Alasdair J.G. Gray^d, Carole Goble^b, Lee Harland^c, Steve Pettifer^b http://dx.doi.org/10.1016/j.websem.2014.03.003}

























https://dev.openphacts.org/

OpenPHACTS API

Chemical Structure Exact Search	/structure/exact GET
InchiKey to URL	/structure GET
Inchi to URL	/structure GET
Chemical Structure Similarity Search	/structure/similarity GET
SMILES to URL	/structure GET
Chemical Structure Substructure Search	/structure/substructure GET
Get concept description	/getConceptDescription GET
Map free text to a concept URL based on semantic tag	/search/byTag 🖼
Map URL	/mapURL GET
Map free text to a concept URL	/search/freetext GI
Get ChEBI Ontology Class Members	/compound/chebi/members
Get ChEBI Ontology Root Classes	/compound/chebi/root CET
Get ChEBI Ontology Class	/compound/chebi/node
ChEBI Class Pharmacology Count	/compound/chebi/pharmacology/count GET





Compound Information

Compound Classifications

Compound Pharmacology:

Chemical Structure Search: Similarity

Target Class Pharmacology

Pathway Information: Get Targets

Targets for Disease: List

Tissues for Protein: List

Getting Started Guide:

http://www.slideshare.net/pgroth/ops-developerwebinarjuly312013





Adding Further Value





Directly Funding Public Resources




















HELLO my name is

P12047
X31045








Quality Assurance





ChemSpider Validation & Standardization Platform http://bit.ly/NZF5VB





Open PHACTS Explorer Alpha Aspirin Search Browse by Ontology About the Aspirin / Compound Information Provenance On Off

AlogP

H-Bond Acceptors

4

H-Bond Donors

1

Mol Weight

180.157

Aspirin

Structure $C_9H_8O_4$

Draw Molecule

The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)

ChemSpider ID OPS403534

SMILES CC(=0)OC1=CC=CC=C1C(=0)O

Standard InChl InChl=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)

Standard InChIKey BSYNRYMUTXBXSQ-UHFFFAOYSA-N

Protein Binding High (99.5%) to albumin. Decreases as plasma salicylate concentration increases, with

reduced plasma albumin concentration or renal dysfunction, and during pregnancy.

Toxicity Oral, mouse: LD₅₀ = 250 mg/kg; Oral, rabbit: LD₅₀ = 1010

mg/kg; Oral, rat: LD₅₀ = 200 mg/kg. Effects of overdose include: tinnitus, abdominal pain, hypokalemia, hypoglycemia, pyrexia, hyperventilation, dysrhythmia,

hypotension, hallucination, renal failure, confusion, seizure, coma, and death.








Aspirin

Home / Aspirin / Compound Information



AlogP 1.19 *





Mol Weight

180.157

Aspirin

Pharmacology (2677)

Structure

Draw Molecule

The prototypical analgesic us antipyretic properties and act biosynthesis of prostaglandins arterial and venous thrombosis



This XML file does not appear to have any style information associated with it. The document tree is shown

```
▼<result format="linked-data-api" version="0.2" href="http://ops.few.vu.nl/compound?u
 4ed1d7bdf9d5">
 v<primaryTopic href="http://www.conceptwiki.org/concept/38932552-111f-4a4e-a46a-4ed">http://www.conceptwiki.org/concept/38932552-111f-4a4e-a46a-4ed
    <prefLabel xml:lang="en">Sorafenib</prefLabel></prefLabel>
   ▼ <exactMatch>
      <item href="http://www.conceptwiki.org/concept/38932552-111f-4a4e-a46a-4edld7bd</pre>
     ▼<item href="http://rdf.chemspider.com/187440">
       <ro5_violations datatype="double">0.0</ro5_violations>
        <psa datatype="double">9.235E-18</psa>
        <logp datatype="double">4.818</logp>
        <hbd datatype="double">3.0</hbd>
        <hba datatype="double">7.0</hba>
        <inDataset href="http://www.chemspider.com"/>
       <smiles>0</smiles>
        <inchikey>MLDQJTXFUGDVEO-UHFFFAOYSA-N</inchikey>
       <inchi>0</inchi>
      </item>
    ▼<item href="http://data.kasabi.com/dataset/chembl-rdf/chemblid/CHEMBL1336">
        <inDataset href="http://data.kasabi.com/dataset/chembl-rdf"/>
        <rtb datatype="int">6</rtb>
        <mw freebase datatype="double">464.825</mw freebase>
        <molform>C21H16C1F3N4O3</molform>
        <full_mwt datatype="double">464.825</full_mwt>
    ▼<item href="http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00398">
       <toxicity>0</toxicity>
        cproteinBinding>99.5%</proteinBinding>
        <description>0</description>
        <biotransformation>0</biotransformation>
        <inDataset href="http://linkedlifedata.com/resource/drugbank"/>
      </item>
    </exactMatch>
    <inDataset href="http://www.conceptwiki.org"/>
  </primaryTopic>
  <extendedMetadataVersion href="http://ops.few.vu.nl/compound?uri=http%3A%2F%2Fwww.</pre>
  4ed1d7bdf9d5& metadata=all%2Cviews%2Cformats%2Cexecution%2Cbindings%2Csite"/>
  <definition href="http://ops.few.vu.nl/api-config"/>
 </result>
```

ChemSpider ID OPS403534

Toxicity

SMILES CC(=0)OC1=CC=CC=C1C(=0)O | |

Standard InChi InChi=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11

Standard InChiKey BSYNRYMUTXBXSQ-UHFFFAOYSA-N 🔆

Protein Binding High (99.5%) to albumin. Decreases as plasma salicylate concentration increases with


reduced plasma albumin concentration or renal dysfunction, and during pregrancy.

Oral, mouse: LD₅₀ = 250 mg/kg; Oral, rabbit: LD₅₀ = 1010 mg/kg; Oral, rat: LD₅₀ = 200 mg/kg. Effects of overdose include: tinnitus,

abdominal pain hypokalomia hyposhypomia pyrovia hypopyontilation dyszbythmia












Is Anybody Using It?





API Hits (April 2013 – March 2014)












Explorer2



ChemBioNavigator Target Dossier



Pharmatrek



Helium



MOE



Collector



Cytophacts



Utopia



Garfield



SciBite



KNIME



Mol. Data Sheets



PipelinePilot



scinav.it



Taverna







ChemBio Navigator




http://chembionavigator.com






Pharmatrek (http://pharmatrek.org)







Utopia http://getutopia.org
























































SEQUENOMICS

syngenta

AstraZeneca Partner Community











orphanet













ontoforce







Advancing the Chemical Sciences

Maastricht University





code^N



















inte:ligand







Moving Forward



OPF is a not-for-profit membership organisation, supporting the Open PHACTS Discovery Platform:

A sustainable, open, vibrant and interoperable information infrastructure for applied life science research and development.

To reduce the barriers to drug discovery in industry, academia and for small businesses, the Open PHACTS Discovery Platform provides tools and services to interact with multiple integrated and publicly available data sources. To integrate this data, extensive cross-referencing of scientific concepts is needed across all databases.

The Open PHACTS Foundation ensures the sustainability of the Open PHACTS Discovery Platform infrastructure and acts as a hub for relevant scientific research and development.


















Key Resources

▲ Open PHACTS API

5 Open PHACTS Repository

Subscribe to the Foundation Newsletter

email address

Subscribe

Contact us

info@openphactsfoundation.org

➤ Twitter: @Open PHACTS





Sustainability

Open PHACTS Collaboration Commercial Industry Grants






Wait A Minute Its Free – Why Pay?







https://github.com/openphacts

Membership Benefits



The not-for-profit Foundation maintains the Open PHACTS Discovery Platform, a versatile infrastructure of integrated biomedical data, and actively engages an ecosystem of industry and academic semantic web experts.

Integrated data:
Pharmacological
Physicochemical
Disease Gene
Pathways

Steer the direction

- Prioritise new projects
- Get involved with Foundation governance
- Identify development opportunities
- Propose new data sources to include
- Develop new use-cases and workflows

Training opportunities

Enjoy training opportunities by experts.

Early access to releases

Members have early access to infrastructure and platform updates and new releases, including a locally installable system

Engage a community of experts and peers

The Foundation serves a unique and vibrant scientific community, facilitating collaboration between the pharma industry, academia & SMEs.

Influence the security policy









The (Immediate) Future Of Open PHACTS

- Establish the Open PHACTS foundation
- Recruit members and partners
- Further develop scientific resources
 - Open chemical patent data (SureChEMBL)
 - Gene-Disease associations (DisGeNet)
 - Develop the Open PHACTS VM
- Connect with other projects (IMI+beyond)

Thanks!

Acknowledgements



Pfizer Limited

Universität Wien

Technical University of Denmark

University of Hamburg, Center for Bioinformatics

BioSolveIT GmBH

Consorci Mar Parc de Salut de Barcelona

Leiden University Medical Centre

Royal Society of Chemistry

Vrije Universiteit Amsterdam

Spanish National Cancer Research Centre

University of Manchester

Maastricht University

Aqnowledge

University of Santiago de Compostela

Rheinische Friedrich-Wilhelms-Universität Bonn

Domi

AstraZeneca

GlaxoSmithKline

Esteve

Novartis

Merck Serono

H. Lundbeck A/S

Eli Lilly

Netherlands Bioinformatics Centre

Swiss Institute of Bioinformatics

ConnectedDiscovery

EMBL-European Bioinformatics Institute

Janssen

OpenLink








































































Science-Driven Dynamic Integration



"What are the physiochemical properties of warfarin salts, tautomers or stereo-isomers?"



"What are the biological responses to warfarin?"

Scientific Lenses over Linked Data: An approach to support task specific views of the data.

A vision.

Christian Brenninkmeijer¹, Chris Evelo², Carole Goble¹, Alasdair J G Gray¹, Paul Groth³, Steve Pettifer¹, Robert Stevens¹, Antony J Williams⁴, and Egon L Willighagen²